Daptomycin

證據等級: L5

預測適應症: 10 個

Daptomycin: From Gram-Positive Bacterial Infections to Osteoarthritis (Low-Confidence Signal)

One-Sentence Summary

Daptomycin is a cyclic lipopeptide antibiotic used to treat Gram-positive infections such as skin infections, bacteraemia, and right-sided endocarditis. The TxGNN model's top prediction is Osteoarthritis, but the supporting literature consists entirely of studies on osteoarticular/prosthetic joint infection treatment — not osteoarthritis itself — suggesting this signal is likely an entity-confusion artefact rather than genuine repurposing evidence. A biologically more plausible (but still preclinical) signal exists at rank 2 for Rheumatoid Arthritis.

Quick Overview

Item	Content
Original Indication	Not formally recorded (drug not marketed in Norway); per literature, daptomycin is approved for Gram-positive infections including skin infections, bacteraemia, and right-sided endocarditis
Predicted New Indication	Osteoarthritis
TxGNN Prediction Score	99.86% (rank 1948)
Evidence Level	L4
Norway Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available (blocked pending DrugBank query — see Data Gap DG002). Based on known information, daptomycin is a cyclic lipopeptide antibiotic that depolarizes the bacterial cell membrane, producing a bactericidal effect specific to Gram-positive organisms. This mechanism has no established biological link to the cartilage degradation and low-grade inflammatory processes that drive osteoarthritis (OA).

Critically, every piece of literature supporting the top-ranked "osteoarthritis" prediction is actually about osteoarticular infection or prosthetic joint infection (PJI) — i.e., antibiotic treatment and susceptibility of S. aureus/S. epidermidis in infected joints — not about osteoarthritis pathophysiology or treatment. This strongly suggests the knowledge graph has conflated the entities "osteoarticular infection" and "osteoarthritis," producing a high-confidence but likely spurious prediction. One outlier case report even involves Corynebacterium septic arthritis in a patient originally worked up for OA, further illustrating this confusion.

By contrast, the rank-2 prediction (Rheumatoid Arthritis) is supported by two 2025 preclinical studies showing daptomycin suppresses inflammatory cytokines and NF-κB signalling in a collagen-induced arthritis mouse model, and that structurally optimized daptomycin derivatives have enhanced anti-RA activity in vivo. This represents a genuine, if early-stage, mechanistic hypothesis (immunomodulation independent of antibacterial activity) and is arguably the more scientifically interesting signal in this evidence pack, despite its lower TxGNN score.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
23519823	2013	Cohort	Int Orthop	High-dose daptomycin + rifampicin for Gram-positive osteoarticular infections (not OA treatment)
22511636	2012	Cohort	J Antimicrob Chemother	Daptomycin for knee/hip prosthetic joint infections
26235888	2015	Cohort	Int J Antimicrob Agents	High-dose daptomycin (>6 mg/kg) for complicated bone/joint and implant infections
17999973	2008	Cohort	J Antimicrob Chemother	Daptomycin vs standard therapy for osteoarticular infections with S. aureus bacteraemia
22854340	2012	In vitro	J Antibiot	In vitro susceptibility of S. aureus/S. epidermidis from prosthetic joint infections
21477701	2010	Registry/Cohort	Med Clin (Barc)	EU-CORE registry: Spanish real-world daptomycin use across Gram-positive infections
32206362	2020	Case Report	Case Rep Orthop	Chronic Corynebacterium striatum septic arthritis initially referred for OA/TKA workup
23312602	2013	Cohort	Int J Antimicrob Agents	Survey of prosthetic joint infection management practices (antibiotic choice)
25650692	2015	Cohort	Surg Infect	10-year microbiologic profile of Staphylococci in osteoarticular infections
41853106	2026	Case Report	ASM Case Rep	First reported Corynebacterium propinquum septic arthritis in a native joint

Note: None of the above literature addresses osteoarthritis pathophysiology or treatment efficacy; all relate to bacterial osteoarticular/prosthetic joint infections, reinforcing the assessment that this is an entity-confusion artefact.

Norway Market Information

Daptomycin is currently not marketed in Norway (0 authorizations on file); no product license records are available.

Safety Considerations

Data Gap (Blocking): TFDA-equivalent package insert warnings and contraindications have not yet been retrieved (Data Gap DG001), so a formal S1 safety pre-assessment cannot proceed.
Literature Safety Signal: One case report (PMID 36693494) describes daptomycin-induced rhabdomyolysis complicated by acute gouty arthritis, consistent with daptomycin's known dose-related creatine kinase (CK) elevation toxicity. This appeared as a rank-4 TxGNN "gout" prediction but is properly interpreted as an adverse-event signal, not a therapeutic indication.
Drug Interaction Data: Not found in the current evidence pack (query status: not_found).

Conclusion and Next Steps

Decision: Hold

Rationale: The top-ranked prediction (osteoarthritis) is supported only by literature on unrelated osteoarticular infections, indicating a likely knowledge-graph entity-confusion artefact rather than genuine repurposing evidence. The one mechanistically credible signal (rheumatoid arthritis, rank 2) is still at the animal-model stage with no clinical trials. Combined with the absence of TFDA-equivalent safety data and the drug's unmarketed status in Norway, there is insufficient evidence to advance to formal evaluation.

To proceed, the following is needed:

TFDA-equivalent warnings/contraindications data (blocking — DG001)
Confirmed mechanism of action from DrugBank (DG002)
Independent validation (in vivo/in vitro replication or early clinical data) of the daptomycin anti-inflammatory/NF-κB signal in rheumatoid arthritis before considering it a research priority over the osteoarthritis signal
Drug-drug interaction data
Clarification with the TxGNN knowledge graph team on possible entity overlap between "osteoarticular infection" and "osteoarthritis"
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.